Allele frequencies of CAPN10 SNPs in Finland
A. Marker | Allele | Botnia I | Botnia II | Pooled | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Type 2 diabetes | Control subjects | P | Type 2 diabetes | Control subjects | P | Type 2 diabetes | Control subjects | P | ||||||||
SNP-44 | 1 (T) | 293 (78.3) | 288 (75.0) | 0.28 | 327 (80.5) | 173 (81.6) | 0.75 | 620 (79.5) | 461 (77.3) | 0.34 | ||||||
2 (C) | 81 (21.7) | 96 (25.0) | 79 (19.5) | 39 (18.4) | 160 (20.5) | 135 (22.7) | ||||||||||
SNP-43 | 1 (G) | 294 (76.6) | 259 (67.4) | 0.0049 | 301 (74.5) | 153 (72.9) | 0.66 | 595 (75.5) | 412 (69.4) | 0.011 | ||||||
2 (A) | 90 (23.4) | 125 (32.6) | 103 (25.5) | 57 (27.1) | 193 (24.5) | 182 (30.6) | ||||||||||
SNP-19 | 2 (ins) | 217 (56.5) | 236 (61.5) | 0.16 | 229 (56.4) | 112 (52.8) | 0.40 | 446 (56.5) | 348 (58.4) | 0.47 | ||||||
1 (del) | 167 (43.5) | 148 (38.5) | 177 (43.6) | 100 (47.2) | 344 (43.5) | 248 (41.6) | ||||||||||
SNP-63 | 1 (C) | 356 (92.7) | 369 (96.6) | 0.017 | 346 (85.2) | 183 (86.3) | 0.71 | 702 (88.9) | 552 (92.9) | 0.010 | ||||||
2 (T) | 28 (7.3) | 13 (3.4) | 60 (14.8) | 29 (13.7) | 88 (11.1) | 42 (7.1) |
Data are n (%). All SNPs were genotyped in 395 patients with type 2 diabetes and 298 control subjects. In all, 0.3% of the genotypes could not be provided despite repeated genotyping. Allele frequencies of SNP-43 and -44 did not significantly differ between Botnia I and II samples, whereas SNP-19 allele 1 was more common among control subjects from Botnia II compared with control subjects from Botnia I (47.2 vs. 38.5%; P = 0.041). The SNP-63 allele 2 was substantially more common among both type 2 diabetic patients and control subjects in Botnia II than in Botnia I (14.8 vs 7.3, [P = 0.00080] and 13.7 vs. 3.4% [P = 0.000013] for type 2 diabetic patients and control subjects in Botnia II and I, respectively). All genotype frequencies were in Hardy-Weinberg equilibrium, and those of SNP-43 and -63 differed significantly between type 2 diabetic patients and healthy control subjects (SNP-43: 57.6, 35.8, and 6.6 vs. 48.2, 42.4, and 9.4%; P = 0.039; SNP-63: 79.8, 18.2, and 2.0 vs. 87.2, 11.5, and 1.4%, P = 0.036 for genotypes 11, 12, and 22, respectively).